207 related articles for article (PubMed ID: 23605952)
1. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.
Kantarjian HM; Martinelli G; Jabbour EJ; Quintás-Cardama A; Ando K; Bay JO; Wei A; Gröpper S; Papayannidis C; Owen K; Pike L; Schmitt N; Stockman PK; Giagounidis A;
Cancer; 2013 Jul; 119(14):2611-9. PubMed ID: 23605952
[TBL] [Abstract][Full Text] [Related]
2. Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.
Kantarjian HM; Sekeres MA; Ribrag V; Rousselot P; Garcia-Manero G; Jabbour EJ; Owen K; Stockman PK; Oliver SD
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):559-67. PubMed ID: 23763917
[TBL] [Abstract][Full Text] [Related]
3. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.
Löwenberg B; Muus P; Ossenkoppele G; Rousselot P; Cahn JY; Ifrah N; Martinelli G; Amadori S; Berman E; Sonneveld P; Jongen-Lavrencic M; Rigaudeau S; Stockman P; Goudie A; Faderl S; Jabbour E; Kantarjian H
Blood; 2011 Dec; 118(23):6030-6. PubMed ID: 21976672
[TBL] [Abstract][Full Text] [Related]
4. A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia.
Tsuboi K; Yokozawa T; Sakura T; Watanabe T; Fujisawa S; Yamauchi T; Uike N; Ando K; Kihara R; Tobinai K; Asou H; Hotta T; Miyawaki S
Leuk Res; 2011 Oct; 35(10):1384-9. PubMed ID: 21565405
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia.
Dennis M; Davies M; Oliver S; D'Souza R; Pike L; Stockman P
Cancer Chemother Pharmacol; 2012 Sep; 70(3):461-9. PubMed ID: 22864876
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Heuser M; Smith BD; Fiedler W; Sekeres MA; Montesinos P; Leber B; Merchant A; Papayannidis C; Pérez-Simón JA; Hoang CJ; O'Brien T; Ma WW; Zeremski M; O'Connell A; Chan G; Cortes JE
Ann Hematol; 2021 May; 100(5):1181-1194. PubMed ID: 33740113
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.
Schwartz GK; Carvajal RD; Midgley R; Rodig SJ; Stockman PK; Ataman O; Wilson D; Das S; Shapiro GI
Invest New Drugs; 2013 Apr; 31(2):370-80. PubMed ID: 22661287
[TBL] [Abstract][Full Text] [Related]
8. A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Dennis M; Burnett A; Hills R; Thomas I; Ariti C; Severinsen MT; Hemmaway C; Greaves P; Clark RE; Copland M; Russell N;
Br J Haematol; 2021 Jul; 194(2):298-308. PubMed ID: 33961292
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Kantarjian HM; Thomas XG; Dmoszynska A; Wierzbowska A; Mazur G; Mayer J; Gau JP; Chou WC; Buckstein R; Cermak J; Kuo CY; Oriol A; Ravandi F; Faderl S; Delaunay J; Lysák D; Minden M; Arthur C
J Clin Oncol; 2012 Jul; 30(21):2670-7. PubMed ID: 22689805
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Grundy M; Seedhouse C; Russell NH; Pallis M
BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
[TBL] [Abstract][Full Text] [Related]
12. Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
Floc'h N; Ashton S; Taylor P; Trueman D; Harris E; Odedra R; Maratea K; Derbyshire N; Caddy J; Jacobs VN; Hattersley M; Wen S; Curtis NJ; Pilling JE; Pease EJ; Barry ST
Mol Cancer Ther; 2017 Jun; 16(6):1031-1040. PubMed ID: 28292940
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
Cortes JE; Heidel FH; Fiedler W; Smith BD; Robak T; Montesinos P; Candoni A; Leber B; Sekeres MA; Pollyea DA; Ferdinand R; Ma WW; O'Brien T; O'Connell A; Chan G; Heuser M
J Hematol Oncol; 2020 Jul; 13(1):92. PubMed ID: 32664995
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.
Boss DS; Witteveen PO; van der Sar J; Lolkema MP; Voest EE; Stockman PK; Ataman O; Wilson D; Das S; Schellens JH
Ann Oncol; 2011 Feb; 22(2):431-7. PubMed ID: 20924078
[TBL] [Abstract][Full Text] [Related]
16. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.
Döhner H; Lübbert M; Fiedler W; Fouillard L; Haaland A; Brandwein JM; Lepretre S; Reman O; Turlure P; Ottmann OG; Müller-Tidow C; Krämer A; Raffoux E; Döhner K; Schlenk RF; Voss F; Taube T; Fritsch H; Maertens J
Blood; 2014 Aug; 124(9):1426-33. PubMed ID: 25006120
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.
Collins GP; Eyre TA; Linton KM; Radford J; Vallance GD; Soilleux E; Hatton C
Br J Haematol; 2015 Sep; 170(6):886-90. PubMed ID: 25721307
[No Abstract] [Full Text] [Related]
18. Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells.
Yamauchi T; Uzui K; Shigemi H; Negoro E; Yoshida A; Ueda T
Cancer Sci; 2013 Jul; 104(7):926-33. PubMed ID: 23557198
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Cortes JE; Heidel FH; Hellmann A; Fiedler W; Smith BD; Robak T; Montesinos P; Pollyea DA; DesJardins P; Ottmann O; Ma WW; Shaik MN; Laird AD; Zeremski M; O'Connell A; Chan G; Heuser M
Leukemia; 2019 Feb; 33(2):379-389. PubMed ID: 30555165
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
Lin S; Shaik N; Chan G; Cortes JE; Ruiz-Garcia A
Cancer Chemother Pharmacol; 2020 Oct; 86(4):451-459. PubMed ID: 32885274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
